SkyePharma

Article Abstract:

SkyePharma has developed a range of techniques for drug delivery, and has contracts with major pharmcaeutical companies. Risks are reduced because of this wide range, and large pharmacetical companies may see SkyePharma as a one-stop shop. SmithKline Beecham has acquired an equity stake in SkyePharma, as has Novartis. SkyePharma has previously had problems, but appears to offer potential for investors as it develops its range of technologies for drug delivery.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Skyepharma

Article Abstract:

Skyepharma specialises in drug delivery, and its Solarase has been approved in the US.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

SkyePharma

Article Abstract:

SkyePharma faces less risk than most biotechnology firms, and has arranged a finance deal.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Management, Pharmaceutical industry, Drugs, SkyePharma
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.